• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Betting on Fallen Angels Could Be Heavenly

If you have an appetite for risk, there are buying opportunities.
By JOHN REESE
Jan 15, 2016 | 08:00 AM EST
Stocks quotes in this article: GSK, LAZ

When the market dives, heading for cover may not be your best bet. For those with an appetite for risk, this is a buying opportunity. Of course, blindly buying a stock that has headed south is a bad idea; many such stocks were probably overpriced or have cloudy futures and may remain underwater for some time.

But judiciously choosing fallen angels now can pay off later. I choose stocks by relying on computerized strategies I created that mirror how some of Wall Street's savviest thinkers invest. One of these strategies is based on "Mr. Contrarian," David Dreman, who made his name by going against the flow. Below are a couple of stocks my Dreman-based strategy likes at this time.

But to limit risk, I chose stocks not only earning the Dreman strategy's approval, but earning hosannas from one other strategy as well. Two strategies proclaiming a stock a good buying opportunity make it worth careful consideration.

The two stocks are GlaxoSmithKline (GSK) and Lazard (LAZ). Glaxo is a global pharmaceutical giant, while Lazard is a notable investment banking house. The Dreman strategy focuses on medium to large companies, which applies to both these names. To determine if a stock is contrarian (out of favor with the market) the stock must pass at least two of the following four tests: a P/E ratio, price-to-cash flow ratio, price-to-book ratio or price-to-dividend ratio that is in the bottom 20% of the market. Glaxo's P/E and price-to-dividend ratios are in this bottom 20% cohort, while Lazard's P/E ratio and price-cash flow ratio meet these bottom-dwelling criteria. (Lazard is part of TheStreet's Growth Seeker portfolio.)

To be sure, the company must be financially strong, as the strategy wants to see a return on equity from among the top third of the 1,500 largest-cap stocks, which is 16.85%. Glaxo's ROE is 187.3%, while Lazard's is 115.9%. Both of these ROEs is very impressive. Also in the companies' favor are strong yields: 6.15% for Glaxo and 4.21% for Lazard.

In addition to the Dreman-based plan, my strategy constructed on the foundation created by James P. O'Shaughnessy strongly favors Glaxo. The company's huge market cap of $97 billion, strong cash flow per share, large number of outstanding shares, large annual sales ($34 billion) and solid dividend all add up to a strong performance, as measured by my O'Shaughnessy strategy.

Lazard gets a nod from my Peter Lynch-modeled strategy, which focuses on the P/E/G ratio (price-to-earnings relative to growth), a measure of how well a stock is priced. A P/E/G of up to 1.0 is acceptable, and below 0.5 is a very strong showing. Lazard's P/E/G is an outstanding 0.16, indicating its stock is extremely well priced.

Given today's market, both these companies have their risks. But they are also operating well and have strong financials and well-priced stocks. These are good reasons to consider investing in these companies at this time.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Reese was long GSK, although positions may change at any time.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

Let's Take a Look at Elevance Health Ahead of Earnings

Bruce Kamich
Jan 24, 2023 3:00 PM EST

What are chart patterns indicating?

Moderna Shares Surge on Promising Vaccine Results

Bruce Kamich
Jan 18, 2023 11:02 AM EST

Let's check the charts and indicators.

This Pharma Presents a Potential 'Lose-Win' Situation for Patients and Investors

Brad Ginesin
Jan 7, 2023 7:00 AM EST

Two in five Americans are obese. Treatments that target obesity directly could be the next blockbuster pharma category.

Walgreens Could Continue to Weaken

Bruce Kamich
Jan 5, 2023 12:56 PM EST

The company reported earnings and the shares have rolled over and turned down.

NovoCure Gaps Sharply Higher for a Breakout: How to Play It

Bruce Kamich
Jan 5, 2023 11:26 AM EST

Let's check out the charts and indicators of both NovoCure and Zai Lab.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 03:06 PM EST BOB LANG

    LEAPS Webinar

    This week, I offered a free webinar session talkin...
  • 02:53 PM EST REAL MONEY

    LIVE EVENT: Chris Versace and "Sarge" Guilfoyle Share Their Stock Market Insights

    This Monday, Jan. 30, at 12 p.m., our very own exp...
  • 04:58 PM EST REAL MONEY

    The Latest AAP Podcast!

    Listen in as AAP Tackles Earnings, the Fed, Recess...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login